Welcome to our dedicated page for Hepion Pharm SEC filings (Ticker: CTRVP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Hepion Pharm's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Hepion Pharm's regulatory disclosures and financial reporting.
Hepion Pharmaceuticals reported a first-quarter 2026 net loss of $810,791, a sharp improvement from $6,105,887 a year earlier, driven mainly by lower general and administrative costs and a much smaller warrant-related fair value loss.
The company generated no revenue and remains pre-commercial. Operating expenses were $798,509, including $70,000 of research and development largely tied to a new Cirna Diagnostics liver-disease diagnostic license, which was expensed as in‑process R&D.
Cash was $2,602,580 at March 31, 2026, aided by a one‑time $1,000,000 refund from a prepaid insurance policy. Hepion subsequently raised $700,000 in an April 21 private placement of 17,500,000 common shares at $0.04 per share, with $250,000 recorded as a subscription liability at quarter‑end.
Management reports an accumulated deficit of $246,908,447 and concludes there is “substantial doubt” about the company’s ability to continue as a going concern without additional capital. The filing also discloses material weaknesses in internal controls and notes the March 16, 2026 resignation of the CEO, followed by a separation agreement providing cash and COBRA benefits.
Hepion Pharmaceuticals reported a first-quarter 2026 net loss of $810,791, a sharp improvement from $6,105,887 a year earlier, driven mainly by lower general and administrative costs and a much smaller warrant-related fair value loss.
The company generated no revenue and remains pre-commercial. Operating expenses were $798,509, including $70,000 of research and development largely tied to a new Cirna Diagnostics liver-disease diagnostic license, which was expensed as in‑process R&D.
Cash was $2,602,580 at March 31, 2026, aided by a one‑time $1,000,000 refund from a prepaid insurance policy. Hepion subsequently raised $700,000 in an April 21 private placement of 17,500,000 common shares at $0.04 per share, with $250,000 recorded as a subscription liability at quarter‑end.
Management reports an accumulated deficit of $246,908,447 and concludes there is “substantial doubt” about the company’s ability to continue as a going concern without additional capital. The filing also discloses material weaknesses in internal controls and notes the March 16, 2026 resignation of the CEO, followed by a separation agreement providing cash and COBRA benefits.
Hepion Pharmaceuticals insider Vincent LoPriore and affiliated entities reported significant ownership of the company’s common stock. LoPriore beneficially owns 6,250,000 shares, equal to 21.46% of Hepion’s common stock, including 5,000,000 shares held through Gravitas Capital LP and 1,250,000 shares held by the Invictus Capital Advisors Pension Plan.
The filing states these shares were acquired for investment purposes for an aggregate purchase price of approximately $250,000. The reporting persons note they may acquire additional shares over time but currently have no other specific plans regarding corporate actions at Hepion.
Hepion Pharmaceuticals insider Vincent LoPriore and affiliated entities reported significant ownership of the company’s common stock. LoPriore beneficially owns 6,250,000 shares, equal to 21.46% of Hepion’s common stock, including 5,000,000 shares held through Gravitas Capital LP and 1,250,000 shares held by the Invictus Capital Advisors Pension Plan.
The filing states these shares were acquired for investment purposes for an aggregate purchase price of approximately $250,000. The reporting persons note they may acquire additional shares over time but currently have no other specific plans regarding corporate actions at Hepion.
Hepion Pharmaceuticals is calling an annual shareholder meeting on June 17, 2026 to elect five directors, ratify its auditor and significantly expand its equity incentive plan. Shareholders are asked to increase the 2023 Omnibus Equity Incentive Plan reserve to 8,000,000 shares, up from 200,000, an increase of 7,800,000 shares. The company notes this would equal about 21.5% of basic shares outstanding and 19.7% on a fully diluted basis as of April 28, 2026. The proxy outlines governance practices, board and committee structure, director biographies, executive pay for 2024–2025, and a proposal to ratify Grassi & Co., CPAs, P.C. as independent auditor for 2026.
Hepion Pharmaceuticals is calling an annual shareholder meeting on June 17, 2026 to elect five directors, ratify its auditor and significantly expand its equity incentive plan. Shareholders are asked to increase the 2023 Omnibus Equity Incentive Plan reserve to 8,000,000 shares, up from 200,000, an increase of 7,800,000 shares. The company notes this would equal about 21.5% of basic shares outstanding and 19.7% on a fully diluted basis as of April 28, 2026. The proxy outlines governance practices, board and committee structure, director biographies, executive pay for 2024–2025, and a proposal to ratify Grassi & Co., CPAs, P.C. as independent auditor for 2026.
Hepion Pharmaceuticals director Michael J. Purcell bought 1,250,000 shares of common stock in an open-market purchase. He paid $0.04 per share, for a total of about $50,000. Following this transaction, he directly owns 1,250,000 Hepion Pharmaceuticals common shares.
Hepion Pharmaceuticals director Michael J. Purcell bought 1,250,000 shares of common stock in an open-market purchase. He paid $0.04 per share, for a total of about $50,000. Following this transaction, he directly owns 1,250,000 Hepion Pharmaceuticals common shares.
Hepion Pharmaceuticals, Inc. reported insider-related buying of its common stock. Entities associated with Executive Chairman and 10% owner Vincent S. LoPriore completed open-market purchases at $0.04 per share on April 21, 2026.
Invictus Capital Advisors Pension Plan bought 1,250,000 shares, bringing its holdings to 6,250,000 shares, while Gravitas Capital LP bought 5,000,000 shares, resulting in 5,000,000 shares held. Footnotes state Mr. LoPriore has voting and investment power over both entities’ positions.
Hepion Pharmaceuticals, Inc. reported insider-related buying of its common stock. Entities associated with Executive Chairman and 10% owner Vincent S. LoPriore completed open-market purchases at $0.04 per share on April 21, 2026.
Invictus Capital Advisors Pension Plan bought 1,250,000 shares, bringing its holdings to 6,250,000 shares, while Gravitas Capital LP bought 5,000,000 shares, resulting in 5,000,000 shares held. Footnotes state Mr. LoPriore has voting and investment power over both entities’ positions.
Hepion Pharmaceuticals director Appajosyula Sireesh bought 1,250,000 shares of common stock in an open-market transaction at $0.04 per share. Following this purchase on April 21, 2026, he holds 1,250,000 shares directly, indicating a newly established reported ownership position.
Hepion Pharmaceuticals director Appajosyula Sireesh bought 1,250,000 shares of common stock in an open-market transaction at $0.04 per share. Following this purchase on April 21, 2026, he holds 1,250,000 shares directly, indicating a newly established reported ownership position.
Hepion Pharmaceuticals interim CEO Gary S. Stetz reported an indirect open-market purchase of 1,250,000 shares of common stock at $0.04 per share. The shares are held through the Stetz Belgiovine CPA 401K F/B/O Gary S. Stetz account, and this filing shows total indirect holdings of 1,250,000 shares after the transaction.
Hepion Pharmaceuticals interim CEO Gary S. Stetz reported an indirect open-market purchase of 1,250,000 shares of common stock at $0.04 per share. The shares are held through the Stetz Belgiovine CPA 401K F/B/O Gary S. Stetz account, and this filing shows total indirect holdings of 1,250,000 shares after the transaction.
Hepion Pharmaceuticals, Inc. entered into securities purchase agreements with accredited investors for a private placement of common stock. The company agreed to sell an aggregate of 17,500,000 shares of common stock at an offering price of $0.04 per share, for gross proceeds of $700,000.
The transaction closed on April 21, 2026. The shares were issued in an unregistered offering relying on exemptions under Section 4(a)(2) of the Securities Act and/or Rule 506(b) of Regulation D, meaning they cannot be freely resold in the United States without registration or a valid exemption.
Hepion Pharmaceuticals, Inc. entered into securities purchase agreements with accredited investors for a private placement of common stock. The company agreed to sell an aggregate of 17,500,000 shares of common stock at an offering price of $0.04 per share, for gross proceeds of $700,000.
The transaction closed on April 21, 2026. The shares were issued in an unregistered offering relying on exemptions under Section 4(a)(2) of the Securities Act and/or Rule 506(b) of Regulation D, meaning they cannot be freely resold in the United States without registration or a valid exemption.
Hepion Pharmaceuticals, Inc. reported leadership changes and a separation package for its former chief executive. The company entered into a separation agreement with former CEO Dr. Kaouthar Lbiati effective April 13, 2026, following her earlier resignation for personal reasons.
Under this agreement, Dr. Lbiati will receive $225,000, a $30,625 payment representing the pro‑rated portion of her potential cash bonus, and reimbursement of her COBRA health insurance payments for six months. She also agreed to a general release and confidentiality provisions. On the same date, Dr. Lbiati resigned as a director of the company, leaving both her executive and board roles.
Hepion Pharmaceuticals, Inc. reported leadership changes and a separation package for its former chief executive. The company entered into a separation agreement with former CEO Dr. Kaouthar Lbiati effective April 13, 2026, following her earlier resignation for personal reasons.
Under this agreement, Dr. Lbiati will receive $225,000, a $30,625 payment representing the pro‑rated portion of her potential cash bonus, and reimbursement of her COBRA health insurance payments for six months. She also agreed to a general release and confidentiality provisions. On the same date, Dr. Lbiati resigned as a director of the company, leaving both her executive and board roles.
Hepion Pharmaceuticals, Inc. director and Chief Executive Officer Gary S. Stetz filed an initial statement of beneficial ownership on Form 3. The filing lists him as both a director and officer of the company but does not report any specific holdings or transactions in this excerpt.